Holen Sie sich die Stockscreener-App
12.87
28.32%
2.84
Vorhandelsmarkt:
12.51
-0.36
-2.80%
Schlusskurs vom Vortag:
$10.03
Offen:
$10.12
24-Stunden-Volumen:
12.25M
Relative Volume:
4.70
Marktkapitalisierung:
$1.33B
Einnahmen:
$133.67M
Nettoeinkommen (Verlust:
$-151.76M
KGV:
-8.6643
EPS:
-1.4854
Netto-Cashflow:
$-124.86M
1W Leistung:
+17.75%
1M Leistung:
+19.83%
6M Leistung:
+73.68%
1J Leistung:
+49.65%
1-Tages-Spanne:
$10.02
$13.06
1-Wochen-Bereich:
$9.97
$13.06
52-Wochen-Spanne:
$5.635
$13.20
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Firmenname
Day One Biopharmaceuticals Inc
Sektor
Branche
Telefon
650 484-0899
Adresse
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.87 | 1.04B | 133.67M | -151.76M | -124.86M | -1.4854 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Fortgesetzt | TD Cowen | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-09 | Bestätigt | Needham | Buy |
| 2024-08-01 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-04-24 | Bestätigt | Needham | Buy |
| 2023-04-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-08 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-03 | Eingeleitet | Oppenheimer | Perform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
Alle ansehen
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
Why Day One Biopharmaceuticals (DAWN) Is Up 17.7% After Positive EU Opinion For OJEMDA Approval - simplywall.st
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise - Stocktwits
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 26.2%What's Next? - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Competitors - Meyka
DAWN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Day One Highlights OJEMDA’s EMA Progress, Updates Strategy - TipRanks
Day One Biopharmaceuticals updates presentation after CHMP positive opinion for OJEMDA; 2026 revenue guidance $225–250M - TradingView
Surging OJEMDA sales and EU backing drive Day One (Nasdaq: DAWN) outlook - Stock Titan
Day One Weighs OJEMDA Momentum Against Expanded Oncology Pipeline Risks - Sahm
DAWN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead (NASDAQ:DAWN) - Seeking Alpha
Research Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis: Exploring 113.62% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Day One Biopharmaceuticals (DAWN) Touts Narrower Q4 Loss Challenging Bearish Profitability Narratives - simplywall.st
Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook - Intellectia AI
Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
What Analysts Are Saying About Day One Biopharmaceutical Stock - Benzinga
Needham lowers Day One Biopharmaceuticals price target on costs - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Earnings Miss - MarketBeat
Day One Q4 Net Loss Narrows As OJEMDA Sales Jump 82%; Reaffirms FY26 Guidance; Stock Down - Nasdaq
Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock - MarketBeat
Needham & Company LLC Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $17.00 - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Day One Biopharmaceuticals price target to $22 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DAWN) 2026-02-25 - Seeking Alpha
Day One Biopharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Day One Biopharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Australia
Day One Biopharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Day One Biopharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Day One Biopharmaceuticals Q4 Loss Narrows, Revenue Rises; Shares Drop After Hours - marketscreener.com
Day One Highlights Transformational 2025 and OJEMDA Growth - TipRanks
Day One Biopharmaceuticals beats revenue estimates By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals beats revenue estimates - Investing.com
Day One Bio (DAWN) Q4 2025 Earnings Transcript - The Globe and Mail
First Solar Q4 net sales reach $1.68 billion, analysts expected $1.56 billion - Bitget
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance - Bitget
Lucid Group's Q4 revenue was $522.7 million, exceeding analysts' expectations of $459.4 million. - Bitget
Day One Biopharma (NASDAQ: DAWN) grows OJEMDA franchise and ADC oncology pipeline - Stock Titan
Earnings Flash (DAWN) Day One Biopharmaceuticals, Inc. Reports Q4 Revenue $52.8M, vs. FactSet Est of $49.8M - marketscreener.com
Day One Reports Fourth Quarter and Full Year 2025 Financial - GlobeNewswire
First Week of October 16th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One Biopharmaceuticals earnings up next after Mersana deal - Investing.com South Africa
Day One Biopharmaceuticals earnings up next after Mersana deal By Investing.com - Investing.com Australia
Day One Biopharmaceuticals Inc. (Day One) has officially disclosed its financial report for the fourth quarter and full year of fiscal 2025. - Bitget
Why (DAWN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Examining the Future: Day One Biopharmaceutical's Earnings Outlook - Benzinga
Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q4 2025 Result - GuruFocus
Finanzdaten der Day One Biopharmaceuticals Inc-Aktie (DAWN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):